Evolving regulatory landscape with erythropoiesis-stimulating agents and impact on managed care.
Fatodu
Hugh
H
Director of Pharmacy, Johns Hopkins Healthcare, 6704 Curtis Ct, Glen Burnie, MD 21060, USA. fatoduh@jhhc.com
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D002318:Cardiovascular Diseases / Q000139:chemically induced; D004335:Drug and Narcotic Control; D064420:Drug-Related Side Effects and Adverse Reactions; D006397:Hematinics / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007349:Insurance, Health, Reimbursement; D007676:Kidney Failure, Chronic / Q000150:complications; D008329:Managed Care Programs; D009369:Neoplasms / Q000150:complications; D011358:Product Surveillance, Postmarketing; D018570:Risk Assessment; D020521:Stroke / Q000139:chemically induced; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
D006397:Hematinics